News Focus
News Focus
Followers 158
Posts 6565
Boards Moderated 1
Alias Born 08/06/2004

Re: jmvho post# 358621

Wednesday, 04/27/2022 4:52:29 PM

Wednesday, April 27, 2022 4:52:29 PM

Post# of 517311

Red & plexrec,

I watched this mornings presentation and will say that TGD is coming off as very comfortable and confident in making these presentations. The Stock Twits post sums it up quite well but I also feel TGD is doing a better job of explaining all the upstream
benefits of 2-73 and how much better it is than a drug that just targets amyloid/tau.

Early on in his presentation, he definitely covered the potential prophylactic market,
talking about how the animal studies showed 2-73 prevented AD. Once the MOA
is confirmed in the AD phase 2b/3 trial later this year, Wall Street might finally start
factoring in the enormous size of the prevention market in their calculations for
Anavex.
jmvho



jmvho, thanks for you report. I'm looking forward to seeing the PR on the last patient completing and closing the trial next month. That news should get widely published in the financial news articles. Obviously anyone paying attention has been seeing AVXL left out of Alzheimer articles while other bios in AD programs years behind Anavex getting plenty of ink. When new financial articles are out that Anavex has completed it's trial, that should get this Vol and SP moving up.

Today the XBI being down one percent did not help, Anavex has been pretty much tracking the XBI, however good Alzheimer news should break Anavex away from the XBI down trend.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News